Adimmune Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
For the nine months, sales was TWD 1,667.02 million compared to TWD 848.28 million a year ago. Net income was TWD 230.21 million compared to net loss of TWD 251.8 million a year ago. Basic earnings per share from continuing operations was TWD 0.54 compared to basic loss per share from continuing operations of TWD 0.59 a year ago. Diluted earnings per share from continuing operations was TWD 0.54 compared to diluted loss per share from continuing operations of TWD 0.59 a year ago. Basic earnings per share was TWD 0.54 compared to basic loss per share of TWD 0.59 a year ago. Diluted earnings per share was TWD 0.54 compared to diluted loss per share of TWD 0.59 a year ago.